Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
 
ORIGINAL ARTICLE
Ahead of Print

Clinical significance of elevated antinuclear antibodies in patients with diffuse large B-cell lymphoma: A single center study


1 Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan; Department of Hematology, Jincheng Dayi Hospital, Jincheng, China
2 Department of Hematology, Jincheng People's Hospital, Jincheng, China
3 Department of Hematology, Jincheng Dayi Hospital, Jincheng, China
4 Department of Radiation Oncology, Sichuan Cancer Hospital, Sichuan, Chengdu, China
5 Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China

Correspondence Address:
Hui Sun,
Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Objective: To investigate the potential diagnostic and prognostic values of antinuclear autoantibodies (ANAs) in diffuse large B-cell lymphoma (DLBCL). Materials and Methods: Eighty-two DLBCL patients and 120 healthy controls were selected from the Department of Hematology, Jincheng Dayi Hospital between 2005 and 2014. We examined the expression of ANA in the sera of the 82 DLBCL patients at different Ann-Arbor stages (15 at Stage I, 22 at Stage II, 27 at Stage III, and 18 at Stage IV). ANA detection was performed by immunofluorescence, and the results were confirmed by Western blotting analysis. Result: ANAs were more frequently detected in DLBCL patients than in controls (P < 0.001), with 25 (30.5%) DLBCL patients and 9 (7.5%) controls displaying elevated ANA levels. However, the majority of DLBCL patients in which ANA were detected did not develop autoimmune diseases, suggesting that ANA in DLBCL might not be correlated autoimmune diseases. Furthermore, no correlation was observed between the expression of ANA and the clinical stages of DLBCL. However, ANA-positive DLBCL patients had a better survival rate (P < 0.05). Conclusions: ANA in DLBCL may be a stage-independent prognostic factor rather than an indication for autoimmune diseases and may represent an effective immune response to the tumor.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Lang J
    -  Ma K
    -  Guo J
    -  Zhang J
    -  Wang Q
    -  Sun H
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed252    
    PDF Downloaded21    

Recommend this journal